Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-11-29
2010-12-21
Chung, Susannah (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S505000
Reexamination Certificate
active
07855227
ABSTRACT:
2-Phenylethylamino substituted carboxamide derivatives of formula (I); wherein J, W, R0, R1, R2, R3, and R4have the meanings as defined in the specification and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing them as active ingredient and their use as sodium and/or calcium channel modulators useful in preventing alleviating and curing a wide range of pathologies, including neurological, psychiatric, cardiovascular, inflammatory, ophthalmic, urology, and gastrointestinal diseases where the above mechanisms have been described as playing a pathological role, are described.
REFERENCES:
patent: 3759979 (1973-09-01), Beregi et al.
patent: 5051403 (1991-09-01), Miljanich et al.
patent: 5366982 (1994-11-01), Dereu et al.
patent: 5587454 (1996-12-01), Justice et al.
patent: 5863952 (1999-01-01), Orlek et al.
patent: 5945454 (1999-08-01), Pevarello et al.
patent: 6011035 (2000-01-01), Snutch et al.
patent: 6117841 (2000-09-01), Hu et al.
patent: 6180624 (2001-01-01), Hill
patent: 6187338 (2001-02-01), Caruso et al.
patent: 6207685 (2001-03-01), Lallement et al.
patent: 6242488 (2001-06-01), Bueno et al.
patent: 6281211 (2001-08-01), Cai et al.
patent: 6290986 (2001-09-01), Murdock et al.
patent: 6303819 (2001-10-01), Pevarello et al.
patent: 6326374 (2001-12-01), Magnus et al.
patent: 6326385 (2001-12-01), Wickenden et al.
patent: 6362174 (2002-03-01), Rafferty et al.
patent: 6372792 (2002-04-01), Chouinard
patent: 6380198 (2002-04-01), Lisi
patent: 6420383 (2002-07-01), Henry
patent: 6455538 (2002-09-01), Grauert et al.
patent: 6458781 (2002-10-01), Connor et al.
patent: 6472530 (2002-10-01), Dodd et al.
patent: 6479484 (2002-11-01), Lan et al.
patent: 6500825 (2002-12-01), Lan et al.
patent: 6521647 (2003-02-01), Foster
patent: 7091210 (2006-08-01), Lan et al.
patent: RE40259 (2008-04-01), Pevarello et al.
patent: 2002/0016464 (2002-02-01), Lan et al.
patent: 2004/0248978 (2004-12-01), Salvati
patent: 2006/0079570 (2006-04-01), Salvati et al.
patent: 2007/0093495 (2007-04-01), Ruggero et al.
patent: 2007/0203182 (2007-08-01), Besana et al.
patent: 2008/0096965 (2008-04-01), Barbanti et al.
patent: 20 06 978 (1970-09-01), None
patent: 1588704 (2005-10-01), None
patent: 586 645 (1947-03-01), None
patent: WO 90/14334 (1990-11-01), None
patent: WO 92/01675 (1992-02-01), None
patent: WO 94/08588 (1994-04-01), None
patent: WO 97/10210 (1997-03-01), None
patent: WO 98/35957 (1998-08-01), None
patent: WO 98/40074 (1998-09-01), None
patent: WO 99/14199 (1999-03-01), None
patent: WO 99/26614 (1999-06-01), None
patent: WO 99/35125 (1999-07-01), None
patent: WO 99/55322 (1999-11-01), None
patent: WO 00/02562 (2000-01-01), None
patent: WO 00/02592 (2000-01-01), None
patent: WO 00/53225 (2000-09-01), None
patent: WO 00/57877 (2000-10-01), None
patent: WO 00/61188 (2000-10-01), None
patent: WO 01/07037 (2001-02-01), None
patent: WO 01/45684 (2001-06-01), None
patent: WO 01/74779 (2001-10-01), None
patent: WO 01/98779 (2001-12-01), None
patent: WO 03/018561 (2003-03-01), None
patent: WO 03/020273 (2003-03-01), None
patent: WO 03/037865 (2003-05-01), None
patent: WO 03/057219 (2003-07-01), None
patent: WO 03/091219 (2003-11-01), None
patent: WO 03/091219 (2003-11-01), None
patent: WO 2004/062655 (2004-07-01), None
patent: WO 2004/066987 (2004-08-01), None
patent: WO 2004/066990 (2004-08-01), None
patent: WO 2004/087125 (2004-10-01), None
patent: WO 2004/089353 (2004-10-01), None
patent: WO 2005/018627 (2005-03-01), None
patent: WO 2005/070405 (2005-08-01), None
patent: WO 2006/027052 (2006-03-01), None
Alzheimer, C., 2002, “Na+channels and Ca2+channels of the cell membrane as targets of neuroprotective substances,”Adv. Exp. Med. Biol. 513, 161-181.
Baumann P., 1996, “Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors,”Clin Pharmacokinet31, pp. 444-469.
Bowersox S. Scott et al., 1998, “Pharmacotherapeutic potential of omega-conotoxin MVIIA (SNX-111), an N-type neuronal calcium channel blocker found in the venom ofConus magus,” Toxicon36: 1651-1658.
Catterall, W.A., “Common modes of drug action on Na+channels: local anesthetics, antiarrhythmics and anticonvulsants,”Trends Pharmacol. Sci. (1987) 8: 57-65.
Cizkova D. et al., 2002, “Localization of N-type Ca2+channels in the rat spinal cord following chronic constrictive nerve injury,”Exp. Brain Res. 147: 456-463.
Cooper A. J. et al, 1989, “Tyrarmine and irreversible monoamine oxidase inhibitors in clinical practice,”J Psych Suppl 38-45.
Diaz, Alvaro et al., 1997, “Blockade of spinal N- and P-type, but not L-type, calcium channels inhibits the excitability of rat dorsal horn neurones produced by subcutaneous formalin inflammation,”Pain69: 93-100.
Hatakeyama, Shinji et al., 2001, Differential nociceptive responses in mice lacking the α1Bsubunit of N-type Ca2+channels,Neuroreport12 : 2423-2427.
International Search Report for PCT/EP2006/011443 mailed on May 3, 2007.
Kim, Chanki et al., 2001, “Altered Nociceptive Response in Mice Deficient in the α1BSubunit of the Voltage-Dependent Calcium Channel,”Molecular and Cellular Neuroscience18: 235-245.
Matthews, Elizabeth A. et al., 2001, “Effects of spinally delivered N- and P-type voltage-dependent calcium channel antagonists on dorsal horn neuronal responses in a rat model of neuropathy,”Pain92: 235-246.
Nebe, J. et al., 1998, “Spinal application of ω-contoxin GVIA, an N-type calcium channel antagonist, attenuates enhancement of dorsal spinal neuronal responses caused by intra-articular injection of mustard oil in the rat,”Exp Brain Res120:61-69.
Pevarello P. et al., 1998, “Synthesis and anticonvulsant activity of a new class of 2-[(Arylalkyl) amino] alkanamide Derivatives,”J. Med. Chem. 41: 579-590.
Saegusa, Hironao et al., 2001, Suppression of inflammatory and neuropathic pain symptoms in mice lacking the N-type Ca2+channel,The EMBO Journal, 20: 2349-2356.
Vanegas, Horacio et al., 2000, “Effects of antagonists to high-threshold calcium channels upon spinal mechanisms of pain, hyperalgesia and allodynia,”Pain85, 9-18.
Volz, Hans-Peter et al., 1998, “Monoamine oxidase inhibitors; A perspective on their use in the elderly,”Drugs&Aging13, pp. 341-355.
Yamada et al., 1996, “Pharmacology of antidepressants in the elderly,” Ch. 11 inHandbook of pharmacology of aging, Roberts et al., editors, Boca Raton: CRC Press.
Int'l. Preliminary Report on Patentability and Written Opinion of the Int'l Searching Authority for Int'l. App. No. PCT/EP2006/011443 dated Jul. 7, 2008.
Arban et al., “Evaluation of the Effects of Lamotrigine, Valproate and Carbamazepine in a Rodent Model of Mania,”Behavioural Brain Research158, No. 1:123-132 (Mar. 7, 2005).
Bennett et al., “A Peripheral Mononeuropathy in Rat that Produces Disorders of Pain Sensation Like Those Seen in Man,”Pain33, No. 1:87-107 (Apr. 1988).
Chaplan et al., “Quantitative Assessment of Tactile Allodynia in the Rat Paw,”Journal of Neuroscience Methods53, No. 1:55-63 (Jul. 1994).
Hamill et al., “Improved Patch-Clamp Techniques for High-Resolution Current Recording from Cells and Cell-Free Membrane Patches,”Pflügers Archiv: European Journal of Physiology391, No. 2:85-100 (Aug. 1981).
Pevarello et al., “Synthesis and Anticonvulsant Activity of a New Class of 2-[(arylalky)amino]Alkanamide Derivatives,”Journal of Medicinal Chemistry41, No. 4:579-590. doi:10.1021/jm970599m (Feb. 12, 1998).
Robinson et al., “The Neural Basis of Drug Craving: An Incentive-Sensitization Theory of Addiction,”Brain Res Rev18, 247-91 (1993).
U.S. Appl. No. 60/126,553, filed Mar. 26, 1999, Hogenkamp.
U.S. Appl. No. 10/856,494, filed Jan. 25, 2007, Barbanti.
U.S. Appl. No. 60/126,056, filed Mar. 23, 1999, Prendergast.
Anonymous, “About Post-Herpetic Neuralgia” www.aftershingles.com (2000).
Anonymous, “Cambrid
Caccia Carla
Faravelli Laura
Moriggi Ermanno
Napoletano Mauro
Restivo Alessandra
Chung Susannah
Dechert LLP
Newron Pharmaceuticals S.p.A.
LandOfFree
2-phenylethylamino derivatives as calcium and/or sodium... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2-phenylethylamino derivatives as calcium and/or sodium..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-phenylethylamino derivatives as calcium and/or sodium... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4150305